IP Library › Granted Patent US 11,718,631
Granted Patent B2
US 11,718,631 · App. 16/756,358 · Granted Aug 8, 2023

Sulphonamides and compositions thereof for treating conditions associated with NLRP activity

Inventors: Shankar Venkatraman (Lansdale, PA); Shomir Ghosh (Brookline, MA); William R. Roush (Jupiter, FL); Dong-Ming Shen (Boston, MA); Jason Katz (Newton, MA); Hans Martin Seidel (Concord, MA)
Assignee: Novartis AG
C07D498/04C07C311/51C07D209/04C07D215/14C07D231/12C07D277/30C07D307/54C07D317/46C07D409/12C07D471/04C07D487/04
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,718,631
App. No.
16/756,358
Granted
Aug 8, 2023
Kind
B2
Abstract

In one aspect, compounds of Formula AA, or a pharmaceutically acceptable salt thereof, are featured: wherein the variables shown in Formula AA can be as defined anywhere herein. Compounds AA are modulators of NLRP1 and/or NLRP3

Claims (152)

1. A compound, selected from the group consisting of the compounds below:

Compound

Structure

101

102

106

107

108

109

110

111

112

113

114

115

116

117

118

119

120

121

122

124

125

131

134

137

138

139

140

143

144

145

146

147

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

220

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

301

302

303

304

305

306

307

308

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

330

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

352

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

374

375

376

377

378

379

and pharmaceutically acceptable salts thereof.

2. A pharmaceutical composition comprising a compound or salt as claimed in claim 1 and one or more pharmaceutically acceptable excipients.

Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 5, 2021
From: NOVARTIS INFLAMMASOME RESEARCH, INC.
To: NOVARTIS AG
Reel/Frame 055166/0306 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2020
From: ROUSH, WILLIAM; VENKATRAMAN, SHANKAR; SHEN, DONG-MING; GHOSH, SHOMIR; KATZ, JASON; SEIDEL, HANS MARTIN
To: IFM MANAGEMENT, INC.
Reel/Frame 052962/0001 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 17, 2020
From: IFM MANAGEMENT, INC.
To: NOVARTIS INFLAMMASOME RESEARCH, INC.
Reel/Frame 052962/0054 →
Continuity (2)
Provisional Application 62573562 · Oct 17, 2017
Related Publication 20220340591A1 · Oct 27, 2022